China Independent Clinical Laboratory Industry Report, 2011-2012
Research In China, August 2012, Pages: 50
The independent clinical laboratory industry starts late and is still in its infancy in China, featuring a limited market size of less than RMB2 billion at present which just accounts for 1%-2% of the total revenue of medical diagnosis. Additionally, the independent clinical laboratories in home market can conduct 1,000 or more diagnostic items, while those in a developed country such as the U.S. are capable of carrying out as many as 4,000 diagnostic items. What is worse, China lags far behind developed countries in diagnostic levels, especially in genetic/molecular diagnostics market segment.
Currently, there are roughly 110 independent clinical laboratories in China, but most of them are small sized. Kingmed Diagnostics, Zhejiang D.A. Diagnostics, ADICON Clinical Laboratories, Inc. and Gaoxin-Da An (invested by DAAN Gene) are the leading companies in Chinese independent clinical laboratory industry and adopt comprehensive diagnostic service mode on the basis of chain operation, together making up approximately 70% market share. Although with a small portion of market share, Beijing NYMPHAVN Biotechnology, Beijing Adinovo Genetic Technology and Zhiyuan Medical Inspection Institute occupy a certain position in the market by virtue of special featured diagnostic service.
The demand from downstream market and the introduction of favorable policies like encouraging the development of private medical institutions arouse keen interest of foreign companies in Chinese independent clinical laboratory market. A large number of foreign enterprises have tapped into Chinese market through technical cooperation or direct capital injection.
In early 2012, DAAN Gene (002030) and Life Technologies co-founded Life Technologies DaAn Diagnostics and announced the official launch of DNA sequencing molecular diagnostics project.
In February 2012, Centre Testing International Corporation cooperated with Amcare Labs International in establishing Johns Hopkins (China) Medical Laboratories in Shanghai (registered capital of USD10 million and equity ratio of 51:49) to carry out the independent medical testing service.
In March 2012, Kindstar Global (Beijing) Medical Technology secured USD20 million in Series C funding from such investors as KPCB China, WI Harper Group, Baird Capital Partners Asia and Mayo Clinic, of which the latter three companies also participated in the company’s Series B financing of USD11 million in June 2011.
KEY TOPICS COVERED
- The access policy, industrial policy, international market environment and so forth of Chinese independent clinical laboratory industry;
- Status quo, competitive landscape, prospects and dynamics of Chinese independent clinical laboratory industry;
- The effects of the development of upstream diagnostic reagent and instrument, and downstream medical institutions on Chinese independent clinical laboratory industry;
- Operation, competitive advantages and prospects of 8 independent clinical laboratories including Kingmed Diagnostics, Zhejiang D.A. Diagnostics, ADICON Clinical Laboratories, Inc., DAAN Gene and Kindstar Global (Beijing) Medical Technology, etc.
1 Profile of Independent Clinical Laboratory
1.1 Definition
1.2 Industry Chain
2 Overview of China Independent Clinical Laboratory Industry
2.1 Policies
2.1.1 Access Policies
2.1.2 Industry Policies
2.2 Global Market
2.2.1 Status Quo
2.2.2 Model Enterprises
2.3 Current Development
2.4 Competitive Landscape
2.5 Dynamics and Prospects
3 Upstream and Downstream Industry of China Independent Clinical Laboratory
3.1 Upstream Sector
3.1.1 Status Quo
3.1.2 Product Mix
3.2 Downstream Sector
3.2.1 Huge Market Scale of Chinese Independent Clinical Laboratory
3.2.2 Medical Reform Encourages Rapid Development of Independent Clinical Laboratory in China
3.2.3 Diversified Demand Promotes the Upgrading of Independent Clinical Laboratory Industry in China
4 Key Players in China
4.1 Kingmed Diagnostics Co., Ltd
4.1.1 Profile
4.1.2 Operation and Prospects
4.2 Zhejiang D.A. Diagnostics Co., Ltd
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Clients and Suppliers
4.2.6 R & D and Investment
4.2.7 Independent Clinical Laboratory Service
4.3 DAAN Gene Co., Ltd
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.5 Gross Margin
4.3.6 Independent Clinical Laboratory Service
4.4 Beijing NYMPHAVN Biotechnology Corporation Ltd
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Clients and Suppliers
4.4.6 R & D and Investment
4.5 ADICON Clinical Laboratories, Inc
4.5 Beijing Deyi Biotechnology Medical Co., Ltd
4.6 Beijing Adinovo Genetic Technology Co., Ltd
4.7 Zhiyuan Medical Inspection Institute Co., Ltd
4.8 Kindstar Global (Beijing) Medical Technology Co., Ltd
Selected Charts
Industry Chain of Independent Clinical Laboratory
Comparison of Independent Clinical Laboratory between China and the USA by Undertaker
Policies Concerning Independent Clinical Laboratory Industry in China, 2010-2011
Market Share of Independent Clinical Laboratory Industry in the U.S. by Diagnostic Item, 2003-2010
Market Share of Medical Diagnostics in the USA by Undertaker, 2010
Revenue and Profit of Quest Diagnostics, 2007-2011
Revenue Structure of Quest Diagnostics by Business, 2011
Major M&As of Quest Diagnostics, 2006-2011
Revenue and Profit of Labcorp, 2007-2011
Revenue Breakdown of Labcorp by Business, 2009-2011
Major M&As of Labcorp, 2007-2011
Top 5 Diagnostic Items of Massachusetts General Hospital and Domestic Third-grade Class-A Hospital
Characteristics and Market Share of Major Independent Clinical Laboratories in China, by the End of 2011
Market Size and Growth Rate of In Vitro Diagnostic Industry in China, 2007-2014E
Market Scale and Growth Rate of In Vitro Diagnostic Reagent in China, 2007-2014E
Structure of In Vitro Diagnostic Reagent in China, 2011
Business Revenue and Diagnostics Revenue of Medical Institutions in China, 2010
Number of Visits in Hospitals and Basic Medical Institutions, 2008-2011
Number of Public and Non-public Hospitals in China, 2008-2011
Layout of D.A. Diagnostics’ Independent Clinical Laboratory
Revenue and Profit of D.A. Diagnostics, 2008-2012
Revenue Breakdown of D.A. Diagnostics by Business, 2008-2011
Revenue Structure of D.A. Diagnostics by Business, 2008-2011
Revenue Breakdown of D.A. Diagnostics by Region, 2008-2011
Revenue Structure of D.A. Diagnostics by Region, 2008-2011
Gross Margin of D.A. Diagnostics by Business, 2008-2011
D.A. Diagnostics’ Revenue from Top 5 Clients and % of Total Revenue, 2008-2011
Name List and Revenue Contribution of D.A. Diagnostics’ Top 5 Clients, 2009-2011
D.A. Diagnostics’ Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2011
Name List and Procurement Contribution of D.A. Diagnostics’ Top 5 Suppliers, 2009-2011
R&D Costs and % of Total Revenue of D.A. Diagnostics, 2008-2011
Revenue and Gross Margin of D.A. Diagnostics’ Independent Diagnostics Business, 2008-2011
Revenue and Gross Margin of D.A. Diagnostics’ Independent Diagnostics Business by Product, 2008-2011
Revenue Structure of D.A. Diagnostics’ Independent Diagnostics Business by Client, 2010-2011
Forecast of D.A. Diagnostics’ Revenue by Business, 2011-2014E
Revenue and Profit of DAAN Gene, 2008-2012
Revenue Breakdown of DAAN Gene by Product, 2008-2011
Revenue Structure of DAAN Gene by Region, 2008-2011
Gross Margin of DAAN Gene by Product, 2008-2011
Revenue and Gross Margin Of DAAN Gene’s Independent Diagnostics Business, 2008-2011
Net Assets, Revenue and Net Income of DAAN Gene’s Subsidiaries Engaging in Independent Diagnostics Business, 2011
Revenue and Profit of NYMPHAVN Biotechnology, 2009-2011
Revenue Breakdown of NYMPHAVN Biotechnology by Product, 2009-2011
Revenue Structure of NYMPHAVN Biotechnology by Product, 2009-2011
Revenue Breakdown of NYMPHAVN Biotechnology by Region, 2010-2011
Gross Margin of NYMPHAVN Biotechnology by Product, 2009-2011
NYMPHAVN Biotechnology’s Revenue from Top 5 Clients and % of Total Revenue, 2009-2011
Name List and Revenue Contribution of NYMPHAVN Biotechnology’s Top 5 Clients, 2009-2011
NYMPHAVN Biotechnology’s Procurement from Top 5 Suppliers and % of Total Procurement, 2009-2011
Name List and Procurement Contribution of NYMPHAVN Biotechnology’s Top 5 Suppliers, 2009-2011
R&D Costs and % of Total Revenue of NYMPHAVN Biotechnology, 2009-2011
Distribution and Established Date of Adicon’s Independent Clinical Laboratory
- ADICON Clinical Laboratories, Inc
- Beijing Adinovo Genetic Technology Co., Ltd
- Beijing Deyi Biotechnology Medical Co., Ltd
- Beijing NYMPHAVN Biotechnology Corporation Ltd
- DAAN Gene Co., Ltd
- Kindstar Global (Beijing) Medical Technology Co., Ltd
- Kingmed Diagnostics Co., Ltd
- Zhejiang D.A. Diagnostics Co., Ltd
- Zhiyuan Medical Inspection Institute Co., Ltd
This title is also available in the following language
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW6
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
